In this context, elevated levels of CSF1 and expression of CSF1R have been associated with poor prognosis in different cancers such as breast and ovarian cancer and, consequently, different strategies have emerged to neutralize or inhibit the CSF1/CSF1R signaling in several cancers [20,21,22]. This evidence concerns the gene CSF1R and ovarian carcinoma.